Cognitive behavioural therapy in clozapine-resistant schizophrenia (FOCUS): an assessor-blinded, randomised controlled trial

BACKGROUND: Although clozapine is the treatment of choice for treatment-refractory schizophrenia, 30–40% of patients have an insufficient response, and others are unable to tolerate it. Evidence for any augmentation strategies is scarce. We aimed to determine whether cognitive behavioural therapy (C...

Descripción completa

Detalles Bibliográficos
Autores principales: Morrison, Anthony P, Pyle, Melissa, Gumley, Andrew, Schwannauer, Matthias, Turkington, Douglas, MacLennan, Graeme, Norrie, John, Hudson, Jemma, Bowe, Samantha E, French, Paul, Byrne, Rory, Syrett, Suzy, Dudley, Robert, McLeod, Hamish J, Griffiths, Helen, Barnes, Thomas R E, Davies, Linda, Kingdon, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6063993/
https://www.ncbi.nlm.nih.gov/pubmed/30001930
http://dx.doi.org/10.1016/S2215-0366(18)30184-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6063993/
https://www.ncbi.nlm.nih.gov/pubmed/30001930
http://dx.doi.org/10.1016/S2215-0366(18)30184-6

Ejemplares similares